Biointelect offers consulting services for biopharmaceutical entities looking to commercialise new technologies to support an effective market entry strategy.
💡 Ready to take your idea to the next level but wondering how to fund it? 💡
Register now for the Biointelect Venturer Program!
https://t.co/fqGL5DBaSr
The 2023 courses will be held across 5 states, with the first in Adelaide on Thursday 16th February.
NOVAVAX APPROVED: Nuvaxovid is the first protein-based COVID-19 vaccine registered for use as a booster in Australia.
Novavax, Inc today announced the TGA has granted provisional registration of the Nuvaxovid COVID-19 vaccine as a booster in individuals aged 18 and over. #9News
Novavax will be giving six different presentations showcasing our vaccine data at Australia's Communicable Diseases & Immunisation Conference, #CDIC2022. Learn more: https://t.co/gb61nALTe2
This next episode we discuss with Jennifer Herz from #Biointelect how she and Karl Herz from #Biocelect established their #relationship with @novavax leading to Biocelect being their sponsor for the #covid19vaccine in Australia and New Zealand
@normanswan@englishheadline@normanswan Novavax doses for Australia will be made from the supply network outside the US, so should be no impact;
Each regulator will be making their own assessment of the Novavax vaccine – including the MHRA, EMA and TGA, thanks for your coverage.
Proof that you don’t need hundreds of people or large hospital trusts to recruit for large scale studies. This team of dedicated, wonderful NHS staff has now randomised 638 people to the @Novavax Phase 3 vaccine study and we’re not stopping there. #nextstop650
This morning, we were pleased to announce the signing of a Heads of Terms agreement with the Australian Government for our #COVID#vaccine. Please read our announcement for details: https://t.co/ixUc9lDIf9 #vaccine $NVAX #australia
Great panel discussion just now at @MTPConnect_AUS launch of @AAMRNet_ . @BiointelectInfo can support your business case, project management, grant writing as well as market access strategy for Antimicrobials
$NVAX is very excited to have just announced initiation of the #phase1 portion of the Phase 1/2 clinical trial for #NVXCoV2373, our #COVID19#vaccine . Read our news release to learn more to learn more at https://t.co/bDOaGeRtzt. #novavax2020
In this week of #ICYMI - we feature activities from our CEO @DrDanGrant, our GM Stakeholder Engagement Dr Alfredo Martinez-Coll and our Director Major Projects @ElizabethStares https://t.co/EURwKbVGTw
Encouraging #cancer patients and patient organisations to have their say about funding of new treatments - please complete our survey if you are interested https://t.co/ChlMNKTW30